文献速递湿疹皮炎与荨麻疹

度普利尤单抗联合外用糖皮质激素治疗6至11岁重度特应性皮炎

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
PubMed 文献 · J Am Acad Dermatol · 2020-06-20

这项随机双盲安慰剂对照3期试验纳入367例6至11岁重度特应性皮炎患儿,评估度普利尤单抗联合中效外用糖皮质激素的疗效与安全性。每4周一次和每2周一次两种方案在所有预设终点上均优于安慰剂联合外用糖皮质激素,且疗效呈体重依赖性,结膜炎和注射部位反应更常见。

要点

  • 度普利尤单抗联合外用糖皮质激素可显著改善重度特应性皮炎患儿的体征、症状与生活质量
  • 疗效呈体重依赖,低于30 kg者300 mg每4周、不低于30 kg者200 mg每2周为最佳剂量
  • 结膜炎与注射部位反应在度普利尤单抗组更常见

核心结论

  • 度普利尤单抗联合外用糖皮质激素对重度特应性皮炎患儿有效且耐受性良好,可显著改善体征、症状与生活质量。

研究设计与样本

  • 随机、双盲、安慰剂对照3期试验(NCT03345914),为期16周,367例6至11岁重度特应性皮炎患儿按1:1:1随机分组。
  • 三组分别为300 mg每4周、按体重每2周方案(基线体重低于30 kg用100 mg每2周,不低于30 kg用200 mg每2周)及安慰剂,均联合中效外用糖皮质激素。

主要发现

  • 每4周组、每2周组与安慰剂组分别有32.8%、29.5%、11.4%的患者达到研究者总体评估评分0或1。
  • 每4周组、每2周组与安慰剂组分别有69.7%、67.2%、26.8%的患者达到湿疹面积和严重度指数改善至少75%。
  • 每4周组、每2周组与安慰剂组分别有50.8%、58.3%、12.3%的患者最严重瘙痒评分降低至少4分。
  • 疗效呈体重依赖,低于30 kg者300 mg每4周、不低于30 kg者200 mg每2周为疗效与安全性的最佳剂量。
  • 结膜炎与注射部位反应在度普利尤单抗联合外用糖皮质激素组较安慰剂联合外用糖皮质激素组更常见。

临床怎么用

  • 对局部治疗控制不佳的6至11岁重度特应性皮炎患儿,可考虑度普利尤单抗联合中效外用糖皮质激素,并按体重选择每4周300 mg或每2周200 mg方案。

局限性

  • 治疗期仅16周,为短期观察。
  • 仅纳入重度特应性皮炎患儿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children with severe atopic dermatitis (AD) have limited treatment options. OBJECTIVE: We report the efficacy and safety of dupilumab + topical corticosteroids (TCS) in children aged 6-11 years with severe AD inadequately controlled with topical therapies. METHODS: In this double-blind, 16-week, phase 3 trial (NCT03345914), 367 patients were randomized 1:1:1 to 300 mg dupilumab every 4 weeks (300 mg q4w), a weight-based regimen of dupilumab every 2 weeks (100 mg q2w, baseline weight <30 kg; 200 mg q2w, baseline weight ≥30 kg), or placebo; with concomitant medium-potency TCS. RESULTS: Both the q4w and q2w dupilumab + TCS regimens resulted in clinically meaningful and statistically significant improvement in signs, symptoms, and quality of life (QOL) versus placebo + TCS in all prespecified endpoints. For q4w, q2w, and placebo, 32.8%, 29.5%, and 11.4% of patients, respectively, achieved Investigator's Global Assessment scores of 0 or 1; 69.7%, 67.2%, and 26.8% achieved ≥75% improvement in Eczema Area and Severity Index scores; and 50.8%, 58.3%, and 12.3% achieved ≥4-point reduction in worst itch score. Response to therapy was weight-dependent: optimal dupilumab doses for efficacy and safety were 300 mg q4w in children <30 kg and 200 mg q2w in children ≥30 kg. Conjunctivitis and injection-site reactions were more common with dupilumab + TCS than with placebo + TCS. LIMITATIONS: Short-term 16-week treatment period; severe AD only. CONCLUSION: Dupilumab + TCS is efficacious and well tolerated in children with severe AD, significantly improving signs, symptoms, and QOL.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020. PMID: 32574587. doi:10.1016/j.jaad.2020.06.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。